Scanning Biotech Equities -- Research on ACADIA Pharma, Acorda Therapeutics, Alnylam Pharma, and BioCryst Pharma Editor Note: For more information about this release, please scroll to bottom.
LONDON, June 13, 2014 /PRNewswire/ --
On Thursday, June 12, 2014, the NASDAQ Composite ended at 4,297.63, down 0.79%, the Dow Jones Industrial Average finished the day 0.65% lower at 16,734.19, and the S&P 500 closed at 1,930.11, down 0.71%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 688.58, down 0.56%, while the index has advanced 1.97% in the last one month. Investor-Edge has initiated coverage on the following equities: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Acorda Therapeutics Inc. (NASDAQ: ACOR), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). Free technical research on ACAD, ACOR, ALNY and BCRX can be downloaded upon signing up at:
On Thursday, ACADIA Pharmaceuticals Inc.'s stock recorded a trading volume of 1.12 million shares, lower than its three months average volume of 1.93 million shares. The stock finished the day at $23.03, up 1.01%, and registered an intraday range of $22.40 and $23.89. ACADIA Pharmaceuticals Inc.'s shares have advanced 0.44% in the past three trading sessions and 18.59% in the last one month. However, the stock has declined 7.84% on YTD basis. Furthermore, the company's stock is trading above its 50-day moving average. The stock's 200-day moving average of $23.22 is above its 50-day moving average of $20.33. Additionally, Shares of the company have a Relative Strength Index (RSI) of 64.54. Sign up today to read free research on ACAD at:
Acorda Therapeutics Inc.'s stock gained 1.87%, to close Thursday's session at $35.46, after oscillating between $34.40 and $35.50. The stock recorded a trading volume of 0.24 million shares, below its three months average volume of 0.49 million shares. Over the last one month and from the beginning of 2014, Acorda Therapeutics Inc.'s shares have rallied 15.62% and 21.44%, respectively. However, over the past three months, the company's stock has gone down by 6.36%. The stock is trading above its 50-day and 200-day moving averages. The company stock's 50-day moving average of $33.90 is above its 200-day moving average of $33.57. Further, the company's stock traded at a PE ratio of 78.13 and has an RSI of 58.35. Sign up today to read free research on ACOR at:
On Thursday, Alnylam Pharmaceuticals Inc.'s stock finished the session 0.04% higher at $67.74. A total of 0.62 million shares were traded, which was below its three months average volume of 0.92 million shares. The stock moved between $66.56 and $68.80 during the session. Over the past three trading sessions and last one month, Alnylam Pharmaceuticals Inc.'s shares have advanced 2.70% and 17.79%, respectively. Also, the stock has gained 5.35% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $64.16 is greater than its 50-day moving average of $57.39. Alnylam Pharmaceuticals Inc.'s stock has an RSI of 66.32. Sign up today to read free research on ALNY at:
Shares in BioCryst Pharmaceuticals Inc. fluctuated between $11.27 and $11.88 before ending Thursday's session down 3.12%, at $11.35. The company's stock reported a trading volume of 1.04 million shares, close to its three months average volume of 1.02 million shares. Further, shares of BioCryst Pharmaceuticals Inc. have surged 47.15% over the last one month and 2.12% over the past three months. Also, the stock has gained 49.28% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $9.15 is greater than its 200-day moving average of $8.40. Moreover, shares of the company have an RSI of 72.79. Sign up today to read free research on BCRX at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.